Eli Lilly Navigates a Pivotal Quarter with New Pill and Major Deal

Eli Lilly balances launch of oral GLP-1 drug Foundayo with a major neuroscience acquisition, aiming for growth as stock faces pressure.

Eli Lilly & Co. is steering through a period of intense strategic activity, balancing the high-profile launch of a new oral weight-loss drug with a multi-billion dollar acquisition aimed at building a new growth pillar. The company's moves come as its stock faces pressure, down approximately 12% in recent weeks amid concerns over pricing and growth.

The pharmaceutical giant has officially rolled out its oral GLP-1 receptor agonist, Foundayo (orforglipron), across U.S. pharmacies and its digital platform. This launch marks a strategic shift from injectable therapies to a more accessible tablet form. A key practical advantage, noted by William Blair analyst Andy Hsieh, is that Foundayo can be taken without food restrictions, a potential edge over competing products.

The drug’s efficacy is backed by the Phase 3 ATTAIN-1 trial, where participants on the highest dose achieved an average weight loss of 12.4% over 72 weeks. While this is below the roughly 20% average seen with Lilly's injectable Zepbound, the company is betting on the pill's convenience to capture a broader patient base. To facilitate access, Lilly has implemented a tiered pricing model. Insured patients may pay as little as $25 per month, while cash prices range from $149 to $349 depending on dosage. Expansion into government Medicare programs is targeted for mid-2026.

Simultaneously, Lilly is bolstering its neuroscience division with the planned acquisition of Centessa Pharmaceuticals for $38 per share, a 38% premium to its pre-announcement price. The upfront deal value is approximately $6.3 billion, with an additional $1.5 billion in contingent payments tied to regulatory milestones. The crown jewel of the deal is the drug candidate cleminorexton, an OX2R agonist that has shown promise in Phase 2a studies for narcolepsy and idiopathic hypersomnia. Lilly also sees potential in broader neurological conditions like Alzheimer's and depression.

This push into neuroscience is significant for a segment that generated only about $1.4 billion in revenue for Lilly in 2025, far less than its cardiometabolic, oncology, and immunology units. The company faces competitive pressure, however, as Takeda's rival candidate, oveporexton, is already under FDA priority review and could launch by late 2026. Lilly is betting that cleminorexton's once-daily dosing will prove superior to a twice-daily regimen long-term.

Financially, the company is under scrutiny. Guggenheim recently adjusted its price target slightly downward from $1,168 to $1,163 but maintained a Buy rating. Lilly's own full-year guidance projects revenue between $80 and $83 billion and earnings per share of $33.50 to $35.00. The stock was recently trading at €815.90, reflecting an 11.5% decline since the start of the year.

All eyes are now on April 30, when Eli Lilly reports first-quarter results. Analysts will scrutinize early Foundayo sales; any revenue approaching $500 million for the partial quarter would signal the oral GLP-1 market is expanding faster than anticipated. Management is expected to provide initial patient acceptance data and details on production scaling for the new pill during the subsequent conference call, offering the first concrete read on this critical launch.